LONGITUDINAL STUDY ON LIVER FUNCTIONS IN PATIENTS WITH THALASSEMIA MAJOR BEFORE AND AFTER DEFERASIROX (DFX) THERAPY
With regular blood transfusion and iron chelation therapy, most patients with thalassemia major (BTM) now survive beyond the third decade of life . Liver disease is becoming an important cause of morbidity and mortality in these patients. Chronic hepatitis and/or severe iron overload are important c...
Saved in:
| Main Authors: | Ashraf Tawfik Soliman, Mohamed Yassin, Fawzia AlYafei, Lolwa Al-Naimi, Noora Almarri, Aml Sabt, Vincenzo De Sanctis |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2014-04-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.mjhid.org/index.php/mjhid/article/view/1385 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Combined Deferoxamine - Deferasirox in Treatment of Thalassemia Major with Iron Overload
by: Abdul Kareem A. Mahmood, et al.
Published: (2014-04-01) -
Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-based Case Report
by: Pustika Amalia Wahidiyat, et al.
Published: (2018-06-01) -
Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-based Case Report
by: Pustika Amalia Wahidiyat, et al.
Published: (2018-06-01) -
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
by: Ali Taher
Published: (2018-11-01) -
Efficacy and safety of deferasirox in pediatric patients of thalassemia at a Tertiary Care Teaching Hospital
by: Dhaval R Thakor, et al.
Published: (2017-01-01)